Long-term evolution of anti-INFβ antibodies in IFNβ-treated MS patients: The London, Canada, MS Clinic experience

Neurology

Volumn 61, Issue 9 SUPPL. 5, 2003, Pages

  Kremenchutzky, Marcelo ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA INTERFERON ANTIBODY; INTERFERON ANTIBODY; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; PROTEIN A; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTIGENICITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; ORTHOMYXOVIRUS; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0242579641     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000097294.59963.0e     Document Type: Conference Paper

References (11)

1. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
2. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-894.
3. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta 1a in multiple sclerosis. Neurology 1998;50:1266-1272.
4. Rice GPA, Paszner B, Oger J, Lesaux J, Paty D, Ebers GC. The evolution of neutralizing antibodies in multiples sclerosis patients treated with interferon beta 1b. Neurology 1999;52:1277-1279.
5. Oger J, Paszner BM, Paty DW. Comparison of ELISA with MxA assay for the detection of antibodies to interferon beta and results of long-term follow-up. Neurology 1998;50:A343-A344.
6. Files JG, Gray JL, Do LT, et al. A novel sensitive and selective bioassay for human type I interferons. J Interferon Cytokine Res 1998;18:1019-1024.
7. Giovannoni G, Munschauer FE 3rd, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;73:465-469.
8. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
9. Francis G, Hughes R, King J, et al. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-1636.
10. Stone LA, Frank JA, Albert PS, et al. The effect of interferon beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37:611-619.
11. Paty DW, Goodkin D, Thompson A, Rice G. Guidelines for physicians with patients on IFN-1b: the use of an assay for neutralizing antibody. Neurology 1996;47:865-866.